The Efficacy of ondansetron augmentation in negative sign of Schizophrenia
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT201112125280N7
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
patients who have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks before entry into the study.
Exclusion criteria: Patients who had any medical diagnoses (including ECG conduction abnormalities, neurological disorder, or an active seizure) or were receiving medications that may have affected cognitive performance; Subjects who met the criteria for a DSM IV diagnosis of alcohol or substance abuse (other than for nicotine) within the last month or the criteria for DSM-IV alcohol or substance dependence (other than for nicotine) within the last 6 months; Pregnant or lactating women and those of reproductive age without adequate contraception; psychotropic medications were not allowed for the duration of the study: anticholinergics, sedating antihistaminic, antidepressants, mood stabilizers, or a second antipsychotic (as adjuvant therapy).
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative symptom. Timepoint: base line,weeks 4,8. Method of measurement: PANSS.
- Secondary Outcome Measures
Name Time Method